

## Management of HIV-1 Infection in the Hospital Setting

David J. Weber, MD, MPH; William A. Rutala, PhD, MPH

First described in 1981, the acquired immunodeficiency syndrome (AIDS) has become the major public health problem of the 1980s. The discovery of the etiologic agent responsible for AIDS, the human immunodeficiency virus (HIV-1), allowed the development of serologic tests of infection and has led to an increased understanding of the epidemiology of HIV-1 infection. The rapid increase in the number of infected individuals led to great concern regarding the risks of nosocomial transmission. This editorial is intended as a synopsis of (1) the risks HIV-1-infected patients pose to health care providers, (2) guidelines to minimize these risks, (3) yet-to-be-resolved management issues of caring for the HIV-1-infected patient, and (4) examination of the evidence that suggests HIV-1 infection predisposes to acquisition of nosocomial infections.

### EXTENT OF THE EPIDEMIC

As of August 29, 1988, a total of 72,024 AIDS cases had been reported in the United States.<sup>1</sup> The Public Health Service now projects a cumulative total of 365,000 cases will be diagnosed by the end of 1992, with 263,000 cumulative deaths. In 1992 alone, 80,000 cases are expected to be diagnosed and 66,000 deaths to occur. The Public Health Service estimates that 172,000 AIDS patients will require medical care in 1992 at a cost expected to range from \$5 to \$13 billion dollars.

Unfortunately, the prevalence of HIV infection in the United States is unknown. The Centers for Disease Control estimates that 1 to 1.5 million Americans are currently infected.<sup>1</sup> Data regarding the seroprevalence of HIV infection in the general population have been derived from studies of military personnel, blood donors, pregnant women, and hospitalized patients.<sup>2</sup> Universal screening of military personnel has revealed the following

seroprevalence rates: civilian applicants for military service, 0.14%;<sup>3</sup> US Army reservists, 0.21%;<sup>4</sup> and active-duty personnel, 0.13%.<sup>5</sup> Data collected by the American Red Cross have shown that the overall prevalence among first-time donors of HIV-1 antibodies in the period 1985-1987 was 0.043%.<sup>6</sup> Testing of patients hospitalized predominantly in Midwestern institutions revealed an overall seroprevalence of 0.3% for the first 18,800 persons tested.<sup>1</sup> Testing of newborn blood has revealed the following seroprevalence rates of childbearing women: Massachusetts, 0.21%;<sup>6</sup> New York City, 1.6%;<sup>7</sup> and New York State, 0.8%.<sup>7</sup> Higher rates have been reported from inner-city urban hospitals.<sup>8</sup>

Given the endemic rate of HIV-1 infection in the general population, it was not surprising that several studies provided evidence that health care workers may be exposed to HIV-infected patients or contaminated blood despite the labeling of known infected patients with blood and body fluid precautions. Among 506 patient specimens submitted to a hospital laboratory at an urban teaching hospital in Seattle, hepatitis B surface antigen was present in 6.3%, HIV-1 antibody in 3.0%, or either of these in 8.7%. Among unlabeled specimens, HIV-1 antibody or hepatitis B surface antigen or both were present in 5.7%.<sup>9</sup> Studies in 1986 and 1987 at an inner-city hospital in Baltimore revealed 3.0% and 4.0%, respectively, of patients presenting to the emergency room without a history of HIV-1 infection were in fact seropositive.<sup>10,11</sup> These studies emphasize the need for handling all blood specimens and patients as if contaminated with transmissible agents such as hepatitis B and HIV-1.

### RISKS OF NOSOCOMIAL ACQUISITION OF HIV Reports of Occupational/Nosocomial HIV-1 Infection

Over 20 health care providers have been reported who may have acquired HIV-1 infection through occupational exposure.<sup>12,13</sup> Most workers experienced needlestick injuries but mucous-membrane or nonintact skin contamination were also noted. Although these reports document that HIV-1 infection may be acquired in the hospital setting, the lack of denominator data makes it impossible

---

*From the Division of Infectious Diseases, Department of Medicine, University of North Carolina School of Medicine, and the Department of Hospital Epidemiology, North Carolina Memorial Hospital, Chapel Hill, North Carolina.*

*Address reprint requests to William A. Rutala, PhD, MPH, CB #7030 Burnett-Womack 229H, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7030.*

to develop risk estimates. Other problems with interpreting the significance of these reports include: baseline serum was not available in one third of cases and hence seroconversion could not be determined; heterosexual transmission could not be ruled out in all cases; and inclusion of laboratory workers exposed to high titers of cultured virus may cause inappropriate conclusions to be drawn regarding the risk to health care personnel.

### Seroprevalence Studies of Health Care Personnel

Henderson<sup>14</sup> recently summarized the results of 13 seroprevalence surveys of hospital personnel.<sup>15-27</sup> A total of 6,619 health care workers were screened; 970 persons reported HIV-1-related needlestick exposure and 238 other HIV-1-related exposures. Eight (0.12%) seropositive health care workers were detected who reported no community risk factors. This seroprevalence rate would appear to be similar to those reported in surveys noted above, which are representative of the general population.

A recently published seroprevalence study of hospital personnel in Kinshasa, Zaire, an area of high HIV-1 endemicity, revealed that 8.07% of 2,193 hospital workers were HIV positive compared to 8.4% of 4,890 women attending antenatal clinics and 6.5% of 7,440 male volunteer blood donors. Further, the incidence of new infection between 1984 and 1986 did not vary according to age, sex, or occupational category within the hospital.<sup>28</sup>

### Prospective Studies of HIV-1 Infection in Health Care Personnel Following Exposure to Contaminated Body Fluids

The magnitude of risk of acquiring HIV-1 infection following a direct exposure to contaminated body fluids can best be determined by careful prospective studies. Table 1 summarizes the data currently available from such studies.<sup>29-37</sup> In these studies, six health care workers seroconverted following parenteral injury via a needlestick or sharp object for a risk of 0.40% per exposure or 0.43% per person.

None of 746 exposures involving contamination of a mucous membrane or nonintact skin resulted in seroconversion, yielding a risk of <0.13% per exposure. The actual infection rate following these exposures is likely to be much smaller than the upper bounds shown in Table 1.

### Summary: Risks to Health Care Personnel

Worldwide, HIV-1 is primarily transmitted via sexual encounters, transfusion of blood or blood products, shared needles during intravenous drug use, and vertically from infected mother to child.<sup>38</sup> Studies of household contacts of HIV-1-infected patients have consistently failed to demonstrate that "casual" contact can lead to HIV-1 transmission.<sup>39,40</sup> As opposed to prevalence studies of hepatitis B, prevalence studies of HIV-1 infection have failed to reveal higher infection rates in hospital personnel than studies representative of the general population. Thus, it appears that care of HIV-1-infected patients involving only casual contact would not place hospital personnel at risk for HIV-1 acquisition.

Prospective studies have shown that parenteral exposure to contaminated blood via a needlestick or

TABLE 1  
INCIDENCE OF **SEROCONVERSION** IN HEALTH CARE WORKERS EXPOSED TO BLOOD OR BODY FLUIDS OF PATIENTS INFECTED WITH HIV-1

	Parenteral Exposure To Blood*	Mucous Membrane/Nonintact Skin Contamination
Number of persons exposed	1,404	470
Number of seroconversions	6	0
Risk of seroconversion	0.43% (95% CI, 0.15%-0.84%)†	<0.21% (95% CI, 0%-0.60%)
Number of exposures	1,494	746
Number of seroconversions	6	0
Risk of seroconversion	0.40% (95% CI, 0.14%-0.79%)	<0.13% (95% CI, 0%-0.38%)

\*Abstracted from references 29-37 and personal communications with BJ Fahey and CG Littell.

†Abstracted from references 29, 37-34, 36 and personal communications with BJ Fahey and CG Littell.

‡95% confidence intervals (Poisson distribution).

sharp injury may lead to HIV-1 infection with a risk of approximately 0.4%. Wormser and colleagues have noted that the likelihood of transmission will be determined by the volume and duration of hospitalization of HIV-1-infected persons and the estimated number of needlestick injuries suffered by staff.<sup>41</sup> Based on data at their hospital, they estimate a 30% probability that at least one health care worker will seroconvert per every 105,000 total hospital days for HIV-1-infected patients. Greater emphasis should be placed on reducing needlestick injuries, especially since 31% are preventable by adherence to existing infection control guidelines.<sup>33</sup>

Case reports suggest that mucous membrane or contamination of open wounds may also lead to HIV-1 infection. The magnitude of the risk, however, is below the level of detection in current prospective series. Nevertheless, prevention guidelines have been designed to minimize such exposures.

### NOSOCOMIAL RISKS POSED BY HIV-1-ASSOCIATED INFECTIONS

The later stages of HIV-1 infection are characterized by an increased prevalence of a variety of infections, many of which are incorporated into the Centers for Disease Control case definition of AIDS.<sup>41</sup> Most infectious agents associated with HIV-1 infection, such as *Toxoplasma gondii*, *Mycobacterium avium* complex, *Cryptococcus neoformans*, and *Pneumocystis carinii*, are not believed to represent nosocomial hazards. However, a variety of infectious agents associated with HIV-1 infection may pose a nosocomial hazard to other patients or staff (Table 2). Special

TABLE 2* HIV-1-ASSOCIATED INFECTIONS THAT REPRESENT A NOSOCOMIAL HAZARD	
Infection	Additional Isolation Precautionst (Beyond Universal Precautions)
Pulmonary <i>M tuberculosis</i>	Respiratory
Cutaneous Herpes zoster	Respiratory/Contact
Herpes simplex	Contact
<i>Staphylococcus aureus</i>	Contact (significant disease)
<i>T pallidum</i> (syphilis)	Contact
Gastrointestinal Cryptosporidia	Enteric
<i>Salmonella</i>	Enteric
<i>Shigella</i>	Enteric
Systemic Cytomegalovirus	None
Epstein-Barr virus	None
Hepatitis B	None

\*Adapted from reference 37  
†See reference 54 for discussion of body substance /so/at/on and precautions employed with this system,

vigilance is required to ensure proper precautions are employed, as persons with cutaneous infections due to herpes zoster, herpes simplex, and *Treponema pallidum* may present with unusual manifestations, including an atypical clinical appearance or prolonged duration.

Of special note is the high incidence (5% to 10%) of tuberculosis in HIV-1-infected patients.<sup>43-47</sup> The majority of cases, clinical tuberculosis precedes the development of AIDS (mean time: eight to ten months). Delays in diagnosis and institution of respiratory precautions in these patients is characterized by a higher likelihood of anergy, negative smears and cultures using expectorated sputum, and an atypical chest radiographic appearance. To date, however, nosocomial outbreaks of tuberculosis due to misdiagnosed infection have not been reported.

#### UNRESOLVED MANAGEMENT ISSUES IN CARING FOR THE HIV-1-INFECTED PATIENT

As knowledge has increased regarding transmission routes of HIV, the Centers for Disease Control has continued to develop and publish guidelines to minimize the risk of nosocomial acquisition.<sup>48-53</sup> These and other authoritative guidelines have covered tissue and organ procurement, invasive procedures, management of dialysis patients, laboratories, dentistry, autopsy services, housekeeping, waste disposal, and sterilization/disinfection. The mainstay of preventive measures has been the adoption of universal precautions<sup>14, 18, 49</sup> or body substance isolation.<sup>54</sup>

Despite progress in understanding the transmission of HIV-1, several issues regarding prevention of nosocomial transmission have yet to be resolved: (1) the efficacy of

universal precautions or body substance isolation in preventing worker exposure; (2) the most efficacious and cost-effective method to educate staff regarding the risk of HIV-1 transmission and proper precaution techniques; (3) how to ensure compliance with universal precautions or body substance isolation; (3) do needle disposal containers in patient rooms lead to patient abuses of the needles or lower the rate of needle injuries; (5) the most effective engineering changes of syringes or needles to minimize needlesticks; (6) does leakage through tears in gloves pose a risk for health care personnel; (7) can operative techniques or equipment be altered to minimize or eliminate sharp exposure and splatter of bloody body fluids; and (8) will continuation of prospective studies allow us to determine the risk of seroconversion following contamination of mucous membranes or nonintact skin.

Zidovudine (azidothymidine, AZT) has been shown useful in prolonging life in AIDS patients. Theoretically, it may be useful in reducing the likelihood of HIV-1 acquisition following parenteral exposure, although there is currently no direct laboratory or clinical evidence to support this hypothesis. Burroughs-Wellcome recently initiated a double-blind, placebo-controlled trial in the United States to evaluate the potential effectiveness of prophylactic administration of zidovudine to health care workers recently (<5 days) exposed to HIV-1-infected blood or blood products via sharp injury, or mucous membrane or nonintact skin contamination. Before participating, infection control personnel and injured employees must consider the potential toxicities of drug administration, the risk of HIV-1 acquisition based on current data and type of exposure, and the randomized double-blind nature of the trial. Additional information may be obtained by calling 1-800-HIV-STIK.<sup>55</sup>

#### RISK OF NOSOCOMIAL INFECTION FOR HIV-1-INFECTED PERSONS

Case reports and uncontrolled series have suggested that patients with AIDS or AIDS-related complex (ARC) commonly develop bacterial sepsis<sup>56-61</sup> and bacterial infections involving the respiratory tract,<sup>62,63</sup> gastrointestinal tract,<sup>64</sup> and skin.<sup>65</sup> Few studies have evaluated whether HIV-1-infected patients who have not progressed to AIDS are at increased risk of infection. Such patients reportedly have had unusually severe *Salmonella* infections often associated with bacteremia,<sup>66,67</sup> a higher frequency of bacterial pneumonia,<sup>68</sup> a higher frequency of infectious exzemoïd dermatitis,<sup>69</sup> and an increased incidence of pneumococcal bacteremia.<sup>70</sup> Thus, HIV-1-infected patients may represent a group at high risk of acquiring nosocomial infections.

Only limited data are available regarding frequency of nosocomial infections in hospitalized HIV-1-infected patients. Rates of 9.7%<sup>71</sup> and 11.3%<sup>72</sup> have been reported in HIV-1-infected patients, the majority of whom had progressed to AIDS. Because the studies have not reported nosocomial infection rates for a group of comparably ill non-HIV-infected patients, it is impossible to determine if HIV infection per se predisposed to nosocomial infection.

HIV-1-infected patients undergoing surgery do not

appear to have higher-than-expected rates of surgical wound infections. Wound infection rates of 0%<sup>73</sup> and 2.5%<sup>71</sup> have been reported in AIDS/ARC patients undergoing lymph node biopsies. One wound infection was noted in 15 AIDS patients (6.7%) undergoing splenectomy for thrombocytopenic purpura.<sup>75</sup> Surgery in HIV-1-infected hemophiliacs has not been shown to lead to an increased rate of wound or other nosocomial infections compared with noninfected hemophiliacs.<sup>76</sup> Although the numbers were small, the same study did document that patients with AIDS undergoing invasive procedures had a significantly higher rate of all nosocomial infections compared with asymptomatic HIV-1-infected and non-HIV-1-infected hemophiliacs. AIDS patients undergoing anorectal surgery reportedly have a poor healing rate of 88% and a major complications rate of 16%.<sup>77</sup> Because 18% to 24% of patients with ARC or AIDS have been reported to require surgery,<sup>78,79</sup> the risk of surgery in these patients deserves further study.

As the number of persons being treated for HIV-associated illnesses increases into the 1990s, it is likely that more hospital workers will care for HIV-infected patients. Infection control practitioners can play a major role in educating staff about HIV-1 infection and promoting compassionate and humane care to HIV-1-infected patients. Continued emphasis should be placed on defining and minimizing the risks in managing HIV-1 infection and reducing risks to hospitalized HIV-1-infected patients. Policy formation should be based on the results of carefully conducted experiments and prospective series.

## REFERENCES

1. Centers for Disease Control: Quarterly report to the domestic policy council on the prevalence and rate of spread of HIV and AIDS—United States. *MMWR* 1988; 37:551-559.
2. Centers for Disease Control: Human immunodeficiency infection in the United States: A review of current knowledge. *MMWR* 1987; 36:1-48.
3. Centers for Disease Control: Trends in human immunodeficiency virus infection among civilian applicants for military service—United States, October 1985-March 1988. *MMWR* 1988; 37:677-679.
4. Cowan DN, Brundage JF: Prevalence and demographic determinants of HIV infection among US Army Reserve personnel. Abstract #4642, Fourth International Conference on AIDS, Stockholm, Sweden, June 1988.
5. Centers for Disease Control: Prevalence of human immunodeficiency virus antibody in US active-duty military personnel, April 1988. *MMWR* 1988; 37:461-463.
6. Hoff R, Berardi VP, Weiblen BJ, et al: Seroprevalence of human immunodeficiency virus among childbearing women. *N Engl J Med* 1988; 318:525-530.
7. Centers for Disease Control: Quarterly report to the domestic policy council on the prevalence and rate of spread of HIV and AIDS in the United States. *MMWR* 1988; 37:223-227.
8. Landesman S, Minkoff H, Holman S, et al: Serosurvey of human immunodeficiency virus infection in parturients: Implications for human immunodeficiency virus testing programs of pregnant women. *JAMA* 1987; 258:2701-2703.
9. Handsfield HH, Cummings MJ, Swenson PD: Prevalence of antibody to human immunodeficiency virus and hepatitis B surface antigen in blood samples submitted to a hospital laboratory. *JAMA* 1987; 258:3395-3397.
10. Baker JL, Kelen GD, Sivertson KT, et al: Unsuspected human immunodeficiency virus in critically ill emergency patients. *JAMA* 1987; 257:2609-2611.
11. Kelen GD, Fritz S, Qaqish B, et al: Unrecognized human immunodeficiency virus infection in emergency department patients. *N Engl J Med* 1988; 318:1645-1650.
12. Centers for Disease Control: Update: Acquired immunodeficiency syndrome and human immunodeficiency virus infection among health care workers. *MMWR* 1988; 37:229-239.
13. Cartier F, Ruffault A, Camus C, et al: Needlestick HIV infection in a nurse. Abstract #9010, Fourth International Conference on AIDS, Stockholm, Sweden, June 1988.

14. Henderson DK: AIDS and the health-care worker: Management of human immunodeficiency virus infection in the health care setting. *AIDS Updates* 1988; 1:1-12.
15. Boland M, Keresztes J, Evans P, et al: HIV seroprevalence among nurses caring for children with AIDS/ARC. Abstract THP.212, Third International Conference on Acquired Immunodeficiency Syndrome (AIDS), Washington, DC, June 1987.
16. Ebbesen P, Melbye M, Scheutz F, et al: Lack of antibodies to HTLV-III/LAV in Danish dentists. *JAMA* 1986; 256:2199.
17. Gilmore N, Ballachey ML, O'Shaughnessy M, et al: HTLV-III/LAV serologic survey of health care workers in a Canadian teaching hospital. Abstract #200, Presented at the Second International Conference on AIDS, Paris, France, June 1986.
18. Gerberding JL, Bryant-LeBlanc CE, Nelson K, et al: Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS-related conditions. *J Infect Dis* 1987; 156:1-8.
19. Harper S, Flynn N, Van Horne J, et al: Absence of HIV antibody among dental professionals, surgeons, and household contacts exposed to persons with HIV infection. Abstract THP.215, Third International Conference on Acquired Immunodeficiency Syndrome (AIDS), Washington, DC, June 1987.
20. Hirsch MS, Wormser GP, Schooley RT, et al: Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III). *N Engl J Med* 1985; 312:1-4.
21. Klein RS, Phefan JA, Freeman K, et al: Low occupational risk of human immunodeficiency virus infection among dental professionals. *N Engl J Med* 1988; 318:86-90.
22. Marcus R: CDC's health-care workers surveillance project. Abstract #9015, Fourth International Conference on AIDS, Stockholm, Sweden, June 1988.
23. Shanson DC, Evans R, Lai L: Incidence and risk of transmission of HTLV-III infections to staff at a London hospital, 1982-85. *J Hosp Infect* 1985; 6:15-22.
24. Weiss SH, Saxinger WC, Rechtman D, et al: HTLV-III infection among health care workers—Association with needle-stick injuries. *JAMA* 1985; 254:2089-2093.
25. Weiss SH, Goedert JJ, Gartner S, et al: Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. *Science* 1988; 239:68-71.
26. Weiss SH, Goedert JJ, Sarngadharan MG, et al: Screening test for HTLV-III (AIDS agent) antibodies. *JAMA* 1985; 253:221-225.
27. Lubick HA, Schaeffer LD: Occupational risk of dental personnel survey (letter). *JADA* 1986; 113:10-12.
28. N'Galy B, Ryder RW, Bila K, et al: Human immunodeficiency virus infection among employees in an African hospital. *N Engl J Med* 1988; 319:1123-1127.
29. Henderson DK, Fabey BJ, Saah AJ, et al: Longitudinal assessment of risk for occupational/nosocomial transmission of human immunodeficiency virus, type I in health care workers. Abstract #634, Abstracts of the Twenty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, California, October, 1988.
30. Hernandez E, Gatell JM, Puvuelo T, et al: Risk of transmitting the HIV to health care workers (HCW) exposed to HIV infected body fluids. Abstract #9003, Fourth International Conference on AIDS, Stockholm, Sweden, June 1988.
31. Gerberding JL, Littell CG, Chambers HF: Risk of occupational HIV transmission in intensively exposed health care workers (HCW): Follow-up. Abstract #343, Abstracts of the Twenty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, California, October, 1988.
32. Kuhls TL, Viker S, Parris NB, et al: Occupational risk of HIV, HBV, and HSV-2 infections in health care personnel caring for AIDS patients. *Am J Public Health* 1987; 77:1306-1309.
33. Marcus R, CDC Cooperative Needlestick Surveillance Group: Surveillance of health care workers exposed to blood from patients infected with the human immunodeficiency virus. *N Engl J Med* 1988; 319:1118-1123.
34. McEvoy M, Porter K, Mortimer P, et al: Prospective study of clinical, laboratory, and ancillary staff with accidental exposures to blood or body fluids from patients infected with HIV. *Br Med J* 1987; 294:1595-1597.
35. Pizzocolo G, Stellini R, Cadeo GP, et al: Risk of HIV and HBV infection after accidental needlestick. Abstract #9012, Fourth International Conference on AIDS, Stockholm, Sweden, June 1988.
36. Ramsey KM, Smith EN, Reimarz JA: Prospective evaluation of 44 health care workers exposed to human immunodeficiency virus-1 with one seroconversion. *Clin Res* 1988; 36:22A.
37. Wormser GP, Joline C, Sivak SL, et al: Human immunodeficiency virus infections: Considerations for health care workers. *Bull NY Acad Med* 1988; 64:203-215.
38. Friedland GH, Klein RS: Transmission of the human immunodeficiency virus. *N Engl J Med* 1987; 317:1125-1135.
39. Friedland GH, Saltzman BR, Rogers MF, et al: Lack of transmission of HTLV-III/LAV infection to household contacts of patients with AIDS or AIDS-related complex with oral candidiasis. *N Engl J Med* 1986; 314:344-349.
40. Lifson AR: Do alternate modes for transmission of human immunodeficiency virus exist? *JAMA* 1988; 259:1353-1356.
41. Wormser GP, Rabkin CS, Joline C: Frequency of nosocomial transmission of HIV infection among health care workers. *N Engl J Med* 1988; 319:307-308.
42. Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. *MMWR* 1987; 36:3s-14s.

43. Centers for Disease Control: Tuberculosis and acquired immunodeficiency syndrome—New York City. *MMWR* 1987; 36:785-795.
44. Centers for Disease Control: Tuberculosis and AIDS—Connecticut. *MMWR* 1987; 36:133-135.
45. Centers for Disease Control: Tuberculosis and acquired immunodeficiency syndrome—Florida. *MMWR* 1986; 35:587-590.
46. Handwerker S, Mildvan D, Senie R, et al: Tuberculosis and the acquired immunodeficiency syndrome at a New York City Hospital: 1978-1985. *Chest* 1987; 91:176-180.
47. Louie E, Rice LB, Holzman RS: Tuberculosis in non-Haitian patients with acquired immunodeficiency syndrome. *Chest* 1986; 90:542-545.
48. Centers for Disease Control: Recommendations for prevention of HIV transmission in health-care settings. *MMWR* 1987; 36:38-188.
49. Centers for Disease Control: Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health care settings. *MMWR* 1988; 37:377-382.
50. Centers for Disease Control: Human immunodeficiency virus infection transmitted from an organ donor screened for HIV antibody—North Carolina. *MMWR* 1987; 36:306-308.
51. Centers for Disease Control: 1988 agent summary statement for human immunodeficiency virus and report on laboratory acquired infection with human immunodeficiency virus. *MMWR* 1988; 37(suppl no S-1):1-17.
52. Centers for Disease Control: Semen banking, organ and tissue transplantation, and HIV antibody testing. *MMWR* 1988; 37:57-63.
53. Centers for Disease Control: Transmission of HIV through bone transplantation: Case report and public health recommendations. *MMWR* 1988; 37:597-599.
54. Lynch P, Jackson MM, Cummings MJ, et al: Rethinking the role of isolation practices in the prevention of nosocomial infections. *Ann Intern Med* 1987; 107:243-246.
55. LaFon SW, Lehman SN, Barry DW: Prophylactically administered Retrovir in health care workers potentially exposed to the human immunodeficiency virus. *J Infect Dis* 1988; 158:503.
56. Slim J, Yeh P, Perez G, et al: Bacteremias in AIDS patients. Abstract #7084, Abstracts of the Fourth International Conference on AIDS, Stockholm, Sweden, June 1988.
57. Jacobson MA, Gellermann H, Chambers H: *Staphylococcus aureus* bacteremia (SAB) and recurrent staphylococcal infection in patients with AIDS and ARC. Abstract #7085, Abstracts of the Fourth International Conference on AIDS, Stockholm, Sweden, June, 1988.
58. Krumholz HM, Lo B, Hadley K, et al: Community-acquired bacteremia in AIDS patients: Presentation and outcome. Abstract #7086, Abstracts of the Fourth International Conference on AIDS, Stockholm, Sweden, June 1988.
59. Rolston K, Radentz S, Rodriguez S, et al: Bacterial infections in AIDS patients. Abstract #7083, Abstracts of the Fourth International Conference on AIDS, Stockholm, Sweden, June 1988.
60. Whimbey E, Gold JW, Polsky B, et al: Bacteremia and fungemia in patients with acquired immunodeficiency syndrome. *Ann Intern Med* 1986; 104:511-514.
61. Witt DJ, Craven DE, McCabe WR: Bacterial infections in adult patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex. *Am J Med* 1987; 82:900-906.
62. Krasinski K, Borkowsky W, Bonk S, et al: Bacterial infections in human immunodeficiency virus (HIV) infected children. Abstract THP.145, Abstracts of the Third International Conference on Acquired Immunodeficiency Syndrome (AIDS), Washington DC, June 1987.
63. Polsky B, Gold JWM, Whimbey E, et al: Bacterial pneumonia in patients with acquired immunodeficiency syndrome. *Ann Intern Med* 1986; 104:38-41.
64. Antony MA, Brandt LJ, Klein RS, et al: Infectious causes of diarrhea in patients with AIDS. Abstract F.3.4., Abstracts of the Third International Conference on Acquired Immunodeficiency Syndrome (AIDS), Washington, DC, June 1987.
65. Goodman DS, Teplitz ED, Wishner A, et al: Prevalence of cutaneous disease in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. *J Am Acad Dermatol* 1987; 17:210-220.
66. Glaser JB, Morton-Kute L, Berger SR, et al: Recurrent *Salmonella typhimurium* bacteremia associated with the acquired immunodeficiency syndrome. *Ann Intern Med* 1985; 102:189-193.
67. Jacobs JL, Gold JWM, Murray HW, et al: *Salmonella* infections in patients with the acquired immunodeficiency syndrome. *Ann Intern Med* 1985; 102:186-188.
68. Selwyn PA, Feingold AR, Hartel D, et al: Bacterial pneumonia and HIV infection in parenteral drug users without AIDS. Abstract THP.41, Abstracts of the Third International Conference on Acquired Immunodeficiency Syndrome (AIDS), Washington, DC, June 1987.
69. Valle SL: Dermatologic findings related to human immunodeficiency virus infections in high-risk individuals. *J Am Acad Dermatol* 1987; 17:951-961.
70. Mandell M, Adimora A, Dobkin J: Steep increase in pneumococcal bacteremia at Harlem Hospital from 1982-1987: Probable role of early HIV infection. Abstract #7082, Abstracts of the Fourth International Conference on AIDS, Stockholm, Sweden, June 1988.
71. Farber B, Kaplan MH, Smith M: Nosocomial infections in patients with HIV infection. Abstract #1287, Abstracts of the Twenty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY, October 1987.
72. Mendelson MH, Francis L, Behrman R, et al: Prospective surveillance of bacterial infections in patients with AIDS, ARC, and HIV seropositivity. Abstract L-24, Abstracts of the Annual Meeting of the American Society for Microbiology, Miami Beach, FL, May 1988.
73. Benotti PN, Jenkins RL, Cady B, et al: Surgical approach to generalized lymphadenopathy in homosexual men. *J Surg Oncol* 1987; 36:231-234.
74. Davis JM, Mouradian J, Fernandez RD, et al: Acquired immunodeficiency syndrome. *Arch Surg* 1984; 119:90-95.
75. Schneider PA, Abrams DI, Ravner AA, et al: Immunodeficiency-associated thrombocytopenic purpura (ITP). *Arch Surg* 1987; 122: 1175-1178.
76. Buehrer J, Weber DJ, Meyer AA, et al: Wound infection (WI) rates in HIV+ and HIV- hemophiliacs undergoing invasive procedures. Abstract #1233, Abstracts of the Twenty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, October 1988.
77. Waxner SD, Smithy WB, Milsom JW, et al: The surgical management of anorectal disease in AIDS and pre-AIDS patients. *Dis Colon Rectum* 1986; 29:719-723.
78. Nugent P, O'Connell TX: The surgeon's role in treating acquired immunodeficiency syndrome. *Arch Surg* 1986; 121:1117-1120.
79. Ferguson CM: Surgical complications of human immunodeficiency virus infection. *Am Surg* 1988; 54:4-9.